The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | IPSOS: addressing the unmet needs of elderly patients with lung cancer
Siow Ming Lee, PhD FRCP, University College Hospital London, London, UK, discusses the untreated population of elderly individuals with lung cancer who are underrepresented in immunotherapy trials. Prof. Ming Lee explains that although the median age of lung cancer is 75, most clinical trials have been conducted on individuals with a physical status (PS) of 0-1 and who are 65 years of age or less. The IPSOS trial (NCT03191786), therefore, aims to recruit a real-world population of patients with a median age of 75 to better reflect the lung cancer landscape. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
